Switch to:
Also traded in: UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.72
ICLR's Cash to Debt is ranked lower than
68% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ICLR: 0.72 )
Ranked among companies with meaningful Cash to Debt only.
ICLR' s Cash to Debt Range Over the Past 10 Years
Min: 0.54  Med: 27.26 Max: No Debt
Current: 0.72
Equity to Asset 0.52
ICLR's Equity to Asset is ranked lower than
59% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. ICLR: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
ICLR' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.65 Max: 0.77
Current: 0.52
0.44
0.77
Interest Coverage 29.98
ICLR's Interest Coverage is ranked lower than
62% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 101.95 vs. ICLR: 29.98 )
Ranked among companies with meaningful Interest Coverage only.
ICLR' s Interest Coverage Range Over the Past 10 Years
Min: 17.93  Med: 59.94 Max: 382.53
Current: 29.98
17.93
382.53
F-Score: 7
Z-Score: 5.23
M-Score: -2.94
WACC vs ROIC
5.30%
27.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.44
ICLR's Operating margin (%) is ranked higher than
84% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. ICLR: 18.44 )
Ranked among companies with meaningful Operating margin (%) only.
ICLR' s Operating margin (%) Range Over the Past 10 Years
Min: 3.11  Med: 10.74 Max: 18.44
Current: 18.44
3.11
18.44
Net-margin (%) 15.48
ICLR's Net-margin (%) is ranked higher than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.36 vs. ICLR: 15.48 )
Ranked among companies with meaningful Net-margin (%) only.
ICLR' s Net-margin (%) Range Over the Past 10 Years
Min: 2.42  Med: 8.95 Max: 15.48
Current: 15.48
2.42
15.48
ROE (%) 28.29
ICLR's ROE (%) is ranked higher than
95% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. ICLR: 28.29 )
Ranked among companies with meaningful ROE (%) only.
ICLR' s ROE (%) Range Over the Past 10 Years
Min: 3.39  Med: 15.25 Max: 28.29
Current: 28.29
3.39
28.29
ROA (%) 14.29
ICLR's ROA (%) is ranked higher than
93% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.35 vs. ICLR: 14.29 )
Ranked among companies with meaningful ROA (%) only.
ICLR' s ROA (%) Range Over the Past 10 Years
Min: 2.31  Med: 9.47 Max: 14.75
Current: 14.29
2.31
14.75
ROC (Joel Greenblatt) (%) 103.20
ICLR's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.16 vs. ICLR: 103.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICLR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.45  Med: 41.07 Max: 121.32
Current: 103.2
12.45
121.32
Revenue Growth (3Y)(%) 12.30
ICLR's Revenue Growth (3Y)(%) is ranked higher than
72% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.30 vs. ICLR: 12.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICLR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.6  Med: 12.3 Max: 54.3
Current: 12.3
-14.6
54.3
EBITDA Growth (3Y)(%) 45.00
ICLR's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ICLR: 45.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ICLR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.7 Max: 52.9
Current: 45
0
52.9
EPS Growth (3Y)(%) 62.80
ICLR's EPS Growth (3Y)(%) is ranked higher than
95% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ICLR: 62.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICLR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.2  Med: 5.7 Max: 94.7
Current: 62.8
-34.2
94.7
» ICLR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ICLR Guru Trades in Q3 2015

Ron Baron 1,138,759 sh (unchged)
Chuck Royce 150,700 sh (-3.77%)
Jim Simons 377,460 sh (-30.00%)
» More
Q4 2015

ICLR Guru Trades in Q4 2015

Steven Cohen 77,100 sh (New)
Chuck Royce 150,700 sh (unchged)
Ron Baron 1,084,201 sh (-4.79%)
Jim Simons 113,700 sh (-69.88%)
» More
Q1 2016

ICLR Guru Trades in Q1 2016

Jeremy Grantham 8,100 sh (New)
Steven Cohen Sold Out
Chuck Royce 143,700 sh (-4.64%)
Ron Baron 931,953 sh (-14.04%)
Jim Simons 65,700 sh (-42.22%)
» More
Q2 2016

ICLR Guru Trades in Q2 2016

Steven Cohen 166,900 sh (New)
Jeremy Grantham 26,300 sh (+224.69%)
Jim Simons 153,400 sh (+133.49%)
Chuck Royce 143,700 sh (unchged)
Ron Baron 931,328 sh (-0.07%)
» More
» Details

Insider Trades

Latest Guru Trades with ICLR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:CRL, NYSE:BIO, NAS:VWR, NAS:PRXL, OTCPK:DSRLF, NAS:BRKR, NYSE:ALR, NAS:PRAH, OTCPK:BMXMF, OTCPK:CZMWY, NAS:CPHD, NAS:INCR, NYSE:PKI, NAS:NEOG, NAS:EXAS, NAS:QGEN, OTCPK:ERFSF, NAS:MYGN, NAS:KANG, NAS:AXDX » details
Traded in other countries:0NBW.UK,
Icon PLC is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries.

Icon PLC was incorporated in 1990. The Company is a contract research organization that provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The Company organized, operated and assessed its business in two segments, the clinical research segment and the central laboratory segment. The Clinical Research business specializes in the planning, management, execution and analysis of Phase I - IV clinical trials, ranging from small studies to complex, multinational projects. It also conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial Specific clinical research services. The Company provides laboratory services through its central laboratory business, which includes the Company's central laboratories located in Dublin, New York, India, Singapore and China. The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Belgium, Turkey, Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa. The Company's principal competitors are Covance Inc., PAREXEL International Corporation, Pharmaceutical Product Development Inc., Quintiles Transnational Corporation, inVentiv Health, PRA and INC Research.

Guru Investment Theses on Icon PLC

Meridian Funds Comments on Icon PLC - Dec 17, 2014

ICON (ICLR) manages clinical trials for the biotech, pharmaceutical and medical device industries. Our investment in the company materialized when earnings were pressured by an industry slowdown in clinical trials at the same time that ICON was investing in its own capacity expansion. We viewed the slowdown in demand as temporary, caused by the elimination of many duplicative drug development programs. In addition, we thought ICON’s investments in technology positioned the company to gain market share in a growing industry as pharmaceutical customers increasingly outsourced clinical trial work. Strong stock performance in the quarter was driven by revenue and margins coming in above street estimates and a positive management outlook. We continue to hold shares in ICON based on its positioning as a technology leader in the clinical trial industry and the potential to further expand operating margins

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 17.21
ICLR's P/E(ttm) is ranked higher than
74% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.56 vs. ICLR: 17.21 )
Ranked among companies with meaningful P/E(ttm) only.
ICLR' s P/E(ttm) Range Over the Past 10 Years
Min: 8.07  Med: 17.84 Max: 80.63
Current: 17.21
8.07
80.63
Forward P/E 15.95
ICLR's Forward P/E is ranked higher than
91% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.37 vs. ICLR: 15.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.21
ICLR's PE(NRI) is ranked higher than
74% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. ICLR: 17.21 )
Ranked among companies with meaningful PE(NRI) only.
ICLR' s PE(NRI) Range Over the Past 10 Years
Min: 7.99  Med: 17.81 Max: 80.63
Current: 17.21
7.99
80.63
Price/Owner Earnings (ttm) 20.78
ICLR's Price/Owner Earnings (ttm) is ranked higher than
69% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.21 vs. ICLR: 20.78 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ICLR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.19  Med: 25.06 Max: 437.5
Current: 20.78
6.19
437.5
P/B 4.57
ICLR's P/B is ranked lower than
61% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.59 vs. ICLR: 4.57 )
Ranked among companies with meaningful P/B only.
ICLR' s P/B Range Over the Past 10 Years
Min: 0.54  Med: 2.41 Max: 5.6
Current: 4.57
0.54
5.6
P/S 2.75
ICLR's P/S is ranked higher than
55% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. ICLR: 2.75 )
Ranked among companies with meaningful P/S only.
ICLR' s P/S Range Over the Past 10 Years
Min: 0.61  Med: 1.55 Max: 3.31
Current: 2.75
0.61
3.31
PFCF 19.37
ICLR's PFCF is ranked higher than
67% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.27 vs. ICLR: 19.37 )
Ranked among companies with meaningful PFCF only.
ICLR' s PFCF Range Over the Past 10 Years
Min: 5.84  Med: 19.99 Max: 500.21
Current: 19.37
5.84
500.21
POCF 16.11
ICLR's POCF is ranked higher than
60% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.72 vs. ICLR: 16.11 )
Ranked among companies with meaningful POCF only.
ICLR' s POCF Range Over the Past 10 Years
Min: 4.65  Med: 15.54 Max: 85.38
Current: 16.11
4.65
85.38
EV-to-EBIT 14.27
ICLR's EV-to-EBIT is ranked higher than
66% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. ICLR: 14.27 )
Ranked among companies with meaningful EV-to-EBIT only.
ICLR' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.5  Med: 14.9 Max: 48
Current: 14.27
6.5
48
EV-to-EBITDA 11.86
ICLR's EV-to-EBITDA is ranked higher than
67% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.40 vs. ICLR: 11.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
ICLR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.7  Med: 11.3 Max: 23.6
Current: 11.86
4.7
23.6
PEG 0.58
ICLR's PEG is ranked higher than
97% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.69 vs. ICLR: 0.58 )
Ranked among companies with meaningful PEG only.
ICLR' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 1.44 Max: 8.22
Current: 0.58
0.34
8.22
Shiller P/E 37.36
ICLR's Shiller P/E is ranked higher than
59% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.77 vs. ICLR: 37.36 )
Ranked among companies with meaningful Shiller P/E only.
ICLR' s Shiller P/E Range Over the Past 10 Years
Min: 10.01  Med: 20.97 Max: 48.99
Current: 37.36
10.01
48.99
Current Ratio 1.99
ICLR's Current Ratio is ranked lower than
61% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ICLR: 1.99 )
Ranked among companies with meaningful Current Ratio only.
ICLR' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.99
1.12
3.61
Quick Ratio 1.99
ICLR's Quick Ratio is ranked lower than
55% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ICLR: 1.99 )
Ranked among companies with meaningful Quick Ratio only.
ICLR' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 1.95 Max: 3.61
Current: 1.99
1.12
3.61
Days Sales Outstanding 83.22
ICLR's Days Sales Outstanding is ranked lower than
69% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.25 vs. ICLR: 83.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICLR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.88  Med: 87.76 Max: 94.82
Current: 83.22
66.88
94.82
Days Payable 104.31
ICLR's Days Payable is ranked higher than
77% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. ICLR: 104.31 )
Ranked among companies with meaningful Days Payable only.
ICLR' s Days Payable Range Over the Past 10 Years
Min: 1.98  Med: 11.26 Max: 130.79
Current: 104.31
1.98
130.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
ICLR's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.70 vs. ICLR: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICLR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.5  Med: -2 Max: 16.4
Current: 3
-61.5
16.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 60.50
ICLR's Price/Net Current Asset Value is ranked lower than
95% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.40 vs. ICLR: 60.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICLR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.88  Med: 6.92 Max: 62.04
Current: 60.5
0.88
62.04
Price/Tangible Book 15.89
ICLR's Price/Tangible Book is ranked lower than
84% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.42 vs. ICLR: 15.89 )
Ranked among companies with meaningful Price/Tangible Book only.
ICLR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.64  Med: 3.36 Max: 40.36
Current: 15.89
0.64
40.36
Price/Projected FCF 1.70
ICLR's Price/Projected FCF is ranked higher than
60% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ICLR: 1.70 )
Ranked among companies with meaningful Price/Projected FCF only.
ICLR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.72 Max: 6.7
Current: 1.7
0.52
6.7
Price/Median PS Value 1.75
ICLR's Price/Median PS Value is ranked lower than
87% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.98 vs. ICLR: 1.75 )
Ranked among companies with meaningful Price/Median PS Value only.
ICLR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 0.92 Max: 1.94
Current: 1.75
0.37
1.94
Price/Peter Lynch Fair Value 0.69
ICLR's Price/Peter Lynch Fair Value is ranked higher than
96% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. ICLR: 0.69 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ICLR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.2  Med: 1.26 Max: 3.22
Current: 0.69
0.2
3.22
Price/Graham Number 3.49
ICLR's Price/Graham Number is ranked higher than
51% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. ICLR: 3.49 )
Ranked among companies with meaningful Price/Graham Number only.
ICLR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.42  Med: 1.58 Max: 5.91
Current: 3.49
0.42
5.91
Earnings Yield (Greenblatt) (%) 6.96
ICLR's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.30 vs. ICLR: 6.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICLR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 6.7 Max: 15.4
Current: 6.96
2.1
15.4
Forward Rate of Return (Yacktman) (%) 46.02
ICLR's Forward Rate of Return (Yacktman) (%) is ranked higher than
97% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.58 vs. ICLR: 46.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ICLR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14.9  Med: 9.3 Max: 46.5
Current: 46.02
-14.9
46.5

More Statistics

Revenue (TTM) (Mil) $1,609
EPS (TTM) $ 4.34
Beta0.61
Short Percentage of Float3.51%
52-Week Range $62.31 - 82.47
Shares Outstanding (Mil)55.46

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1,687 1,817 1,930
EPS ($) 4.70 5.19 6.01
EPS w/o NRI ($) 4.70 5.19 6.01
EPS Growth Rate
(3Y to 5Y Estimate)
12.32%
Dividends Per Share ($)
» More Articles for ICLR

Headlines

Articles On GuruFocus.com
Dynamite Comes in Small Packages: 10 Small Caps to Get Explosive Returns Apr 01 2016 
Probable Gainers Of A European Market Bounce Back Jan 25 2015 
Meridian Funds Comments on Icon PLC Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Baron Funds Comments on ICON PLC Jun 10 2013 
Parexcel: Great Growth but a Tough Business Aug 17 2011 
Weekly Guru Bargains Highlights: SD, CREE, AMLN, ICLR, CVD Nov 07 2010 

More From Other Websites
Will This Clinical Researcher Become Next Breakout Medical Stock? Aug 11 2016
PRA Health Sciences Vs. Medpace: How 2 Medical IPOs Stack Up Aug 11 2016
Edited Transcript of ICLR earnings conference call or presentation 26-Jul-16 1:00pm GMT Jul 26 2016
ICON PLC Earnings Call scheduled for 9:00 am ET today Jul 26 2016
Q2 2016 ICON PLC Earnings Release - Time Not Supplied Jul 26 2016
ICON Reports Second Quarter 2016 Results Jul 26 2016
Icon PLC beats Street 2Q forecasts Jul 26 2016
Icon PLC beats Street 2Q forecasts Jul 26 2016
ICON Reports Second Quarter 2016 Results Jul 26 2016
ICON Reports Second Quarter 2016 Results Jul 26 2016
Healthcare Earnings Scheduled on Jul 26: CNC, ICLR, UHS Jul 25 2016
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting Jul 25 2016
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting Jul 25 2016
ETF’s with exposure to ICON Plc : July 19, 2016 Jul 19 2016
ETF’s with exposure to ICON Plc : July 1, 2016 Jul 01 2016
ICON to Acquire Clinical Research Management, Inc. Jun 30 2016
ICON to Acquire Clinical Research Management, Inc. Jun 30 2016
ICON Plc :ICLR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 Jun 28 2016
Healthcare Opportunities in Light of Brexit-Driven Selloff Jun 28 2016
ICON Plc breached its 50 day moving average in a Bullish Manner : ICLR-US : June 27, 2016 Jun 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)